Quercetin is a flavonoid polyphenol abundant in onions, apples, berries, and tea that acts as a pleiotropic immunomodulator through antioxidant, anti-inflammatory, antimicrobial, and catecholamine-extending mechanisms. In cPNI protocols, it serves dual functions: inhibiting COMT (catechol-O-methyltransferase) to prolong catecholamines half-life, and directly suppressing inflammatory cascades via NF-κB inhibition. Its bioavailability depends critically on lactase enzyme activity to cleave quercetin-glucosides for SGLT1-mediated absorption.
Think of quercetin as a versatile maintenance crew in a factory (the body) that does three jobs simultaneously. First, it's a fire extinguisher squad — when inflammatory fires (NF-κB activation) start spreading through the production line, quercetin sprays foam directly on the alarm switch, preventing the factory from broadcasting emergency alerts (cytokine production). Second, it's a mop-up crew for chemical spills — scavenging free radicals (Reactive Oxygen Species) before they corrode machinery. Third, and uniquely, quercetin sabotages the recycling plant (COMT) that normally breaks down the factory's motivational posters (norepinephrine, Adrenaline). By gumming up the COMT shredder, those motivational messages stay on the walls longer — great if workers are sluggish (low catecholamine states), problematic if they're already overstimulated (high stress). But here's the trick: this crew only gets through the factory gates (intestinal absorption) if the security guard (lactase) clips their ID badges (cleaves glucose from quercetin-glucosides), allowing the SGLT1 turnstile to let them in. No lactase? The crew waits outside, mostly ineffective.
Quercetin exists predominantly as quercetin-3-O-glucoside in food sources. Absorption requires:
Lactase-SGLT1 pathway:
- Intestinal brush border lactase (lactase-phlorizin hydrolase) cleaves glucose from quercetin-glucosides → free quercetin + Glucose
- Glucose component co-transported with quercetin via SGLT1 (sodium-glucose cotransporter 1) on enterocyte apical membrane
- Na+ gradient (maintained by basolateral Na+/K+-ATPase) drives glucose uptake, dragging quercetin along
- Quercetin enters portal circulation → hepatic first-pass metabolism (phase II conjugation: glucuronidation, sulfation, methylation)
- Conjugated metabolites circulate systemically; intestinal microbiota can also deglycosylate quercetin, producing absorbable aglycone forms
Lactase-deficient individuals show 40-60% reduced bioavailability because unconjugated quercetin-glucosides are poorly absorbed.
graph TD
A[Quercetin] --> B[Enters Cell]
B --> C[Binds IKK Complex]
C --> D["Prevents IκB Phosphorylation"]
D --> E["IκB Remains Bound to NF-κB"]
E --> F["NF-κB Cannot Translocate to Nucleus"]
F --> G["Blocks Transcription of:"]
G --> H["IL-1β, IL-6, IL-8, TNF-α"]
G --> I[COX-2, iNOS]
G --> J[Adhesion Molecules VCAM-1, ICAM-1]
A --> K[Direct ROS Scavenging]
K --> L[Donates Electrons to Neutralize]
L --> M["Superoxide O2⁻"]
L --> N["Hydroxyl Radicals ·OH"]
L --> O["Peroxynitrite ONOO⁻"]
A --> P[Mast Cell Membrane Stabilization]
P --> Q["Inhibits Ca²⁺ Influx"]
Q --> R[Prevents Degranulation]
R --> S[Reduces Histamine Release]
NF-κB inhibition cascade:
- Quercetin → inhibits IKK (IκB kinase) complex
- IκB remains phosphorylated and bound to NF-κB in cytoplasm
- NF-κB transcription factor (p50/p65 heterodimer) cannot translocate to nucleus
- Result: suppressed transcription of IL-1β, IL-6, IL-8, TNF-α, COX-2, iNOS, VCAM-1
- Measured effect: 50-70% reduction in LPS-induced IL-6 at 50 μM quercetin (in vitro)
Antioxidant mechanism:
- Quercetin's 3',4'-catechol structure + 3-hydroxyl group donate electrons to ROS
- Scavenges superoxide (O2⁻), hydroxyl radicals (·OH), peroxynitrite (ONOO⁻)
- Chelates transition metals (Fe²⁺, Cu²⁺) preventing Fenton reaction: Fe²⁺ + H₂O₂ → Fe³⁺ + ·OH + OH⁻
- Upregulates antioxidant enzymes via Nrf2 pathway: quercetin → stabilizes Nrf2 → nuclear translocation → antioxidant response element (ARE) activation → ↑glutathione peroxidase, ↑SOD, ↑catalase
Mast cell stabilization:
- Inhibits phospholipase C activation → reduced IP3 production → decreased Ca²⁺ release from endoplasmic reticulum
- Blocks Ca²⁺ influx through plasma membrane channels
- Prevents Mast Cell Degranulation → reduced Histamine, tryptase, and cytokine release (IL-4, IL-5, IL-13)
COMT enzyme structure:
- COMT (catechol-O-methyltransferase) methylates catechol-containing compounds: norepinephrine, Adrenaline, Dopamine Release, L-DOPA
- Reaction: catecholamine + S-adenosylmethionine (SAM) → methylated metabolite + S-adenosylhomocysteine (SAH)
- Two isoforms: soluble COMT (S-COMT, cytoplasmic) and membrane-bound COMT (MB-COMT, post-synaptic)
Quercetin as competitive inhibitor:
- Quercetin's catechol B-ring (3',4'-dihydroxy structure) mimics catecholamine catechol groups
- Competes for COMT active site (contains Mg²⁺ cofactor binding catechol substrates)
- IC50 = ~0.5-2 μM for COMT inhibition (achievable with 500-1000 mg oral quercetin)
- Result: extended half-life of norepinephrine (from ~2 min to 4-6 min), Adrenaline (similar extension)
- Increased synaptic catecholamine availability → prolonged adrenergic signaling via α1, α2, β1, β2 Adrenoreceptors
Clinical relevance of COMT polymorphism:
- Val158Met polymorphism: Val/Val = high COMT activity (rapid catecholamine breakdown), Met/Met = low COMT activity (slow breakdown)
- Quercetin supplementation in Val/Val individuals → greater functional impact (normalizes overly fast degradation)
- Met/Met individuals already have slow COMT → quercetin may over-extend catecholamines → anxiety, insomnia, tachycardia
Bacterial targets:
- Mycoplasma pneumoniae, Mycoplasma mycoides: quercetin disrupts bacterial membrane lipid rafts → increased permeability → cell death
- Streptococcus pneumoniae: inhibits bacterial neuraminidase enzyme (prevents sialic acid cleavage from host cell surfaces, blocking adhesion)
- MIC (minimum inhibitory concentration) = 50-100 μg/mL for Mycoplasma species
Antiviral effects:
- Inhibits viral proteases (3CLpro in SARS-CoV-2, reduces viral replication)
- Blocks viral entry by interfering with ACE2 receptor binding
- Suppresses viral-induced cytokine storm via NF-κB inhibition
1. Chronic infections with low catecholamine states:
- Patients with Mycoplasma pneumoniae, recurrent pneumococcal infections, or chronic viral reactivation (EBV)
- Quercetin 1000 mg daily provides dual action: direct antimicrobial + immune support via inflammation suppression
- Combines well with vitamin C (synergistic antioxidant network regeneration) and zinc (immune function)
2. Catecholamine deficiency syndromes:
- ADHD (especially Val/Val COMT genotype), chronic fatigue syndrome, depression with psychomotor retardation
- COMT inhibition extends endogenous catecholamine signaling → improved focus, energy, motivation
- Caution: Avoid in Met/Met COMT, anxiety disorders, insomnia (can worsen sympathetic overdrive)
- Effective dose: 500-1000 mg quercetin with lactase supplementation (or quercetin aglycone forms like isoquercetin)
3. Inflammatory conditions requiring NF-κB suppression:
Historical exposure vs modern deficiency:
- Hunter-gatherer diets provided ~500-1000 mg/day quercetin from wild plants, berries, leafy greens
- Modern Western diet: ~10-25 mg/day (95% reduction due to processed foods, reduced plant diversity)
- This represents an evolutionary mismatch → insufficient phytochemical-mediated immune modulation
- cPNI supplementation (1000 mg) restores ancestral exposure levels, supporting Immunometabolism evolved to expect regular polyphenol input
Monitoring during quercetin therapy:
- IL-6 levels: expect 20-40% reduction in chronic inflammatory states (baseline IL-6 >3 pg/mL)
- CRP: modest reduction (10-15%) over 8-12 weeks
- Catecholamine Resistance: if anxiety or insomnia worsens within 1-2 weeks, suspect COMT over-inhibition (reduce dose or discontinue)
- Blood pressure: monitor in hypertensive patients (quercetin can potentiate antihypertensive effects via vasodilation through eNOS upregulation)
Absorption optimization:
- Take with lactase enzyme (5000-10000 ALU) if lactose intolerant or quercetin-glucoside form used
- Alternative: use quercetin aglycone or isoquercetin (quercetin-3-O-glucoside bound to glucose via different linkage, better absorbed)
- Fat-soluble: take with meals containing healthy fats (olive oil, avocado) for enhanced absorption
- Avoid simultaneous intake with Zinc or Iron supplements (quercetin chelates metals, reducing bioavailability of both)
Contraindications and interactions:
- Avoid in: pregnancy (potential teratogenic effects in animal studies), kidney disease (quercetin metabolites excreted renally)
- Drug interactions: potentiates blood thinners (inhibits platelet aggregation), may interfere with chemotherapy (quercetin can protect cancer cells via antioxidant effects in some contexts)
- COMT inhibitor stacking: do not combine with other COMT inhibitors (EGCG, Luteolin, Rutin) without careful monitoring
- Standard cPNI dose: 1000 mg daily (divided into 500 mg twice daily for sustained plasma levels)
- Bioavailability: requires lactase for quercetin-glucoside cleavage; lactase-deficient individuals absorb 40-60% less
- Absorption mechanism: SGLT1 co-transport with Glucose after lactase hydrolysis
- COMT inhibition IC50: 0.5-2 μM (achievable with 500-1000 mg oral dose; peak plasma ~1-2 μM at 1-3 hours post-dose)
- Catecholamine half-life extension: ~2x prolongation (norepinephrine from 2 min to 4-6 min)
- Antimicrobial MIC: 50-100 μg/mL against Mycoplasma pneumoniae, Mycoplasma mycoides, Streptococcus pneumoniae
- NF-κB suppression: 50-70% reduction in LPS-induced IL-6 production at therapeutic concentrations
- ROS scavenging: quercetin's 3',4'-catechol + 3-hydroxyl groups donate electrons to neutralize superoxide, hydroxyl radicals, peroxynitrite
- Food sources: onions (highest: 300-500 mg/kg), apples (40-100 mg/kg), capers (1800 mg/kg), berries (20-60 mg/kg), tea (10-25 mg/cup)
- Plasma half-life: 3.5 hours (requires twice-daily dosing for sustained effects)
- Evolutionary mismatch: modern intake 10-25 mg/day vs ancestral 500-1000 mg/day (40-100x reduction)
- Genetic consideration: Val158Met COMT polymorphism determines individual response (Val/Val benefits most, Met/Met may experience adverse effects)
- COMT — quercetin competitively inhibits this enzyme via catechol B-ring mimicry, extending catecholamines half-life by ~2x
- catecholamines — norepinephrine and Adrenaline degradation slowed by quercetin, prolonging adrenergic signaling
- SGLT1 — sodium-glucose cotransporter that mediates quercetin-glucoside absorption after lactase cleavage
- lactase — essential enzyme for cleaving glucose from quercetin-glucosides, enabling SGLT1-mediated uptake
- NF-κB — quercetin inhibits IKK complex, preventing NF-κB nuclear translocation and inflammatory gene transcription
- inflammation — broad anti-inflammatory via NF-κB suppression, mast cell stabilization, and ROS scavenging
- IL-6 — production reduced 50-70% by quercetin's NF-κB inhibition in LPS-challenged cells
- TNF-α — inflammatory cytokine suppressed via NF-κB pathway blockade
- COX-2 — gene expression inhibited through NF-κB suppression, reducing prostaglandin synthesis
- Reactive Oxygen Species — quercetin directly scavenges superoxide, hydroxyl radicals, and peroxynitrite via electron donation
- antioxidant — functions as direct ROS scavenger and Nrf2 activator (upregulates glutathione system, SOD, catalase)
- Mast cells — quercetin stabilizes membranes by inhibiting Ca²⁺ influx, preventing degranulation and histamine release
- Histamine — release from mast cells blocked by quercetin's membrane-stabilizing effects
- Mycoplasma pneumoniae — quercetin disrupts bacterial membrane integrity at 50-100 μg/mL MIC
- immune system — modulates via NF-κB suppression, mast cell stabilization, antimicrobial effects, and trained immunity modulation
- polyphenols — quercetin is a flavonoid subclass member, sharing antioxidant and anti-inflammatory mechanisms with other plant polyphenols
- oxidative stress — reduced via direct ROS scavenging and upregulation of endogenous antioxidant enzymes
- gut microbiome — intestinal bacteria (Lactobacillus, Bifidobacterium) can deglycosylate quercetin-glucosides, producing absorbable aglycone
- vitamin C — synergistic antioxidant network partner; quercetin regenerates oxidized vitamin C (dehydroascorbate → ascorbate)
- omega-3 fatty acids — combined in anti-inflammatory protocols; quercetin's NF-κB suppression enhances omega-3 conversion to SPMs
- ADHD — quercetin's COMT inhibition extends dopamine/norepinephrine signaling, improving focus (especially Val/Val genotype)
- chronic fatigue syndrome — catecholamine extension may improve energy and motivation in low-catecholamine phenotypes
- metabolic syndrome — quercetin reduces metaflammation (low-grade inflammation) via NF-κB inhibition and improved insulin sensitivity
- Type 2 Diabetes — anti-inflammatory and insulin-sensitizing effects reduce chronic hyperglycemia-induced oxidative stress
- allergies — mast cell stabilization reduces histamine-mediated allergic symptoms (rhinitis, urticaria)
- asthma — dual benefit from mast cell stabilization and NF-κB suppression (reduces airway inflammation)
- Module 1: Quercetin absorption via lactase-SGLT1 pathway; antimicrobial effects against Mycoplasma species
- Module 2: COMT inhibition extending catecholamine half-life in stress response and chronic fatigue contexts
- Module 5: Anti-inflammatory mechanisms (NF-κB suppression) in chronic disease management